Efficacy

Lorviqua (lorlatinib) Efficacy in Lung Cancer

Lorviqua, also known by its generic name lorlatinib, is a medication specifically indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) designed to inhibit the most common tumor mutations that drive resistance to earlier ALK inhibitors.

The efficacy of Lorviqua in lung cancer has been demonstrated in clinical trials. In a pivotal phase 2 trial, lorlatinib showed substantial antitumor activity in patients with ALK-positive NSCLC who had failed previous ALK inhibitors. The response rates were significant, with a considerable proportion of patients experiencing a reduction in tumor size. Additionally, lorlatinib has been shown to have activity in the central nervous system (CNS), which is particularly important given the propensity for ALK-positive NSCLC to metastasize to the brain.

Cosela (trilaciclib) Efficacy in Lung Cancer

Cosela, with the generic name trilaciclib, is a first-in-class therapy approved to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). Trilaciclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that helps protect bone marrow cells from damage caused by chemotherapy by transiently arresting bone marrow cells in the G1 phase of the cell cycle.

The efficacy of Cosela in lung cancer was evaluated in multiple clinical trials where it was administered before chemotherapy. In these studies, Cosela significantly reduced the incidence of severe neutropenia, which is a common and potentially life-threatening side effect of chemotherapy. By reducing the occurrence of neutropenia, Cosela helps to maintain the dose intensity of chemotherapy, potentially improving outcomes for patients with ES-SCLC. Furthermore, the use of Cosela was associated with a lower need for supportive treatments such as granulocyte colony-stimulating factors (G-CSFs) and red blood cell transfusions.